Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 901–1,000 of 2,517
Mapping the p53 transcriptome universe using p53 natural polymorphs
Wang, B., Niu, D., Lam, T. H., Xiao, Z., & Ren, E. C. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.132 · Cited by 52
Wild-type and mutant p53 proteins interact with mitochondrial caspase-3
Frank, A. K., Pietsch, E. C., Dumont, P., Tao, J., & Murphy, M. E. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.8.14906 · Cited by 47
“R175H is a common structural hotspot mutant of p53 that affects the stabilization of the p53 tetramer.(13,14) In previous studies, R175H was found to be unable to interact with either Bcl2 or Bcl-x l ,(9,15) but retains the ability to interact with Bak.”
BackgroundEntropy Localization in Proteins
Li, D., Showalter, S. A., & Brüschweiler, R. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp109908u · Cited by 49
Olotu, F. A., & Soliman, M. E. S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26430 · Cited by 49
“In addition to the DBD, the p53 protein sequentially consists of the transactivation domain (residues 1-44), tetramerization domain (325-356), and the C-terminal domain (357-393).(5) This core domain consists of a binding surface and a supporting central β sheet containing two β sheets that are anti-parallel.”
BackgroundFimognari, C., Nüsse, M., Lenzi, M., Sciuscio, D., Cantelli‐Forti, G., & Hrelia, P. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.06.001 · Cited by 49
Thyroid Carcinoma Is Characterized by Genomic Instability: Evidence from p53 Mutations
Shahedian, B., Shi, Y., Zou, M., & Farid, N. R. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3114 · Cited by 48
Multiple response elements and differential p53 binding control Perp expression during apoptosis.
Reczek, E. E., Flores, E. R., Tsay, A. S., Attardi, L. D., & Jacks, T. (2003) · PubMed · Cited by 58
Reversal of In Vitro p53 Squelching by both TFIIB and TFIID
Liu, X. E., & Berk, A. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6474 · Cited by 48
“It functions as a typical sequence-specific transcriptional activator (8, 17) that binds as a tetramer (15) to four tandem, alternatively inverted copies of a 5-bp consensus sequence (4, 13).”
BackgroundTumor Suppressor p53 Mediates Apoptotic Cell Death Triggered by Cyclosporin A
Pyrzyńska, B., Serrano, M., Martínez‐A, C., & Kaminska, B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104443200 · Cited by 50
Discrimination of DNA Binding Sites by Mutant p53 Proteins
Thukral, S. K., Lu, Y., Blain, G. C., Harvey, T. S., & Jacobsen, V. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.5196 · Cited by 52
Maurici, D., Monti, P., Campomenosi, P., North, S., Frébourg, T., Fronza, G., & Hainaut, P. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204428 · Cited by 49
“…7 7 7 WR2721 responder E180K L2 + + 7 7 7 +/7 7 +/7 P219L S7 + + +/7 + + + +/7 + D228Vb S7/S8 + + +/7 +/7 + + +/7 + P250L L3 +/7 +/7 7 7 7 7 7 +/7 D259N S9/S10 + + 7 +/7 7 +/7 +/7 + R283H H2 + + 7 +/7 +/7 + +/7 + aLocalization of the mutation in secondary structure motifs of p53 (Cho et al., 1994).”
Backgroundp53 Mutations and Expression in Breast Carcinoma in Situ
Lukas, J. L., Niu, N., & Press, M. F. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64718-9 · Cited by 49
Identification of a novel gene encoding a p53-associated protein
Zhou, R., Wen, H., & Ao, S.-Z. (1999) · Gene · doi:10.1016/s0378-1119(99)00203-6 · Cited by 49
The dominating effect of mutant p53
Hann, B. C., & Lane, D. P. (1995) · Nature Genetics · doi:10.1038/ng0395-221 · Cited by 55
Low, L., Goh, A., Koh, J., Lim, S., & Wang, C.-I. (2019) · Nature Communications · doi:10.1038/s41467-019-13305-z · Cited by 48
Nanotoxicology of common metal oxide based nanomaterials: their ROS‐y and non‐ROS‐y consequences
Setyawati, M. I., Fang, W., Chia, S. L., & Leong, D. T. (2012) · Asia-Pacific Journal of Chemical Engineering · doi:10.1002/apj.1680 · Cited by 49
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
Azmi, A. S., Philip, P. A., Beck, F. W., Wang, Z., Banerjee, S., Wang, S., Yang, D., Sarkar, F. H., & Mohammad, R. M. (2010) · Oncogene · doi:10.1038/onc.2010.403 · Cited by 50
“Zn2þ is coordinated to C176 and H179 of the L2 loop, and to C238 and C242 of the L3 loop (Pavletich et al., 1993; Cho et al., 1994).”
BackgroundLi, G., Wang, R., Gao, J., Deng, K., Wei, J., & Wei, Y. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0698-9 · Cited by 51
“Most p53 mutations map to the DNA-binding domain, therefore, they are unable to activate genes up-regulated by wild-type p53, a loss of function that ultimately leads to unchecked cell division [ 23 ].”
BackgroundReversal of the DNA-Binding-Induced Loop L1 Conformational Switch in an Engineered Human p53 Protein
Emamzadah, S., Tropia, L., Vincenti, I., Falquet, B., & Halazonetis, T. D. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.12.020 · Cited by 47
“So far, all structures of p53 and of its family member p73 have been shown to adopt an extended loop L1 conformation in their apo form [10,22,23] with only one exception, that of C.”
BackgroundInfluentialp53 Binding to Nucleosomal DNA Depends on the Rotational Positioning of DNA Response Element
Sahu, G., Wang, D., Chen, C. B., Zhurkin, V. B., Harrington, R. E., Appella, E., Hager, G. L., & Nagaich, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081182 · Cited by 48
Complex functions of mutant p53 alleles from human prostate cancer
Shi, X.-B., Nesslinger, N. J., Deitch, A. D., Gumerlock, P. H., & White, R. D. (2002) · The Prostate · doi:10.1002/pros.10072 · Cited by 47
Heessen, S., Leonchiks, A., Issaeva, N., Sharipo, A., Selivanova, G., Masucci, M. G., & Dantuma, N. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022306499 · Cited by 49
Jiang, M., Axe, T., Holgate, R., Rubbi, C. P., Okorokov, A. L., Mee, T., & Milner, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204705 · Cited by 40
“The R248W mutation a ects the R248 DNA contact residue of p53 (Cho et al., 1994).”
BackgroundShlomai, J. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.3029 · Cited by 47
“Cys-176, Cys-238, Cys-242, and His-179 coordinate the binding of a zinc ion, which stabilizes the loop=helical structure of the core domain (59).”
InfluentialTP53: the unluckiest of genes?
Joerger, A. C., Stiewe, T., & Soussi, T. (2025) · Cell Death & Differentiation · doi:10.1038/s41418-024-01391-6 · Cited by 51
“…fi ndings and led to this simple binary classi fi cation of common cancer mutations as contact mutations that disrupt amino acids directly contacting DNA (at codons 273 and 248) and structural mutations that destabilize the structure/ conformation of the DBD (at codons 175, 249, or 282) [20 – 22].”
Lin, Z., Yang, W., Zhang, G., Liu, Q., Qiu, B., Cai, Z., & Chen, G. (2011) · Chemical Communications · doi:10.1039/c1cc13146j · Cited by 48
Posttranslational phosphorylation of mutant p53 protein in tumor development
Matsumoto, M., Furihata, M., & Ohtsuki, Y. (2006) · Medical Molecular Morphology · doi:10.1007/s00795-006-0320-0 · Cited by 56
Bazan, V., Bruno, L., Augello, C., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl958 · Cited by 47
“Only rarely have mutations outside exons 5–8 been identified, including those in the introns of the splicing sites, which probably give rise to an aberrant RNA splicing [14].”
BackgroundGhobashi, A. H., & Kamel, M. A. E.-N. (2018) · Journal of Applied Genetics · doi:10.1007/s13353-018-0432-y · Cited by 51
“Depletion of Tip60 reduces the level of acetylation at K120, located in L-loop of DNA binding core domain of p53 (Cho et al. 1994; Huyen et al. 2004), which impairs p53 induced apoptotic proteins activation, such as p53 upregulated modulator of apoptosis (PUMA) and Bcl-2-associated X protein (BAX), which are essential…”
BackgroundThe ‘wildtype’ conformation of p53: epitope mapping using hybrid proteins
Wang, P. L., Sait, F., & Winter, G. P. (2001) · Oncogene · doi:10.1038/sj.onc.1204316 · Cited by 46
“The crystal structures of the core domain whether free, bound to DNA, or bound to another protein (Cho et al., 1994; Gorina and Pavletich, 1996) do not show signi®cant conformational di erences; therefore the simplest explanation for the loss of the PAb1620 epitope is masking by other parts of p53.”
BackgroundConversion of Wild-type p53 Core Domain into a Conformation that Mimics a Hot-spot Mutant
Ishimaru, D., Maia, L. F., Maiolino, L. M., Quesado, P. A., Lopez, P. M., Almeida, F. C. L., Valente, A. P., & Silva, J. L. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.026 · Cited by 48
Anderson, C. W., & Appella, E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00264-3 · Cited by 54
Chevillard, S., Lebeau, J., Pouillart, P., de Toma, C., Beldjord, C., Asselain, B. J. R., Klijanienko, J., Fourquet, A., Magdelénat, H., & Vielh, P. R. (1997) · PubMed · Cited by 46
Cherny, D. I., Striker, G., Subramaniam, V., Jett, S. D., Paleček, E., & Jovin, T. M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3299 · Cited by 47
Yakovleva, T., Pramanik, A., Kawasaki, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100482200 · Cited by 47
Tang, M. S. (1999) · Carcinogenesis · doi:10.1093/carcin/20.6.1085 · Cited by 47
“The crystal structure of the p53 protein has revealed that the amino acids encoded by codons 175, 248, 273 and 282 are important for DNA contact and/or pivotal for the integrity of the p53 protein structure (6, 7 ).”
BackgroundQuaternary structure of the specific p53–DNA complex reveals the mechanism of p53 mutant dominance
Aramayo, R., Sherman, M. B., Brownless, K., Lurz, R., Okorokov, A. L., & Orlova, E. V. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr386 · Cited by 45
“The structure of the p53 core domain bound to a specific DNA explained the target-specific mechanism of DNA recognition by p53 (9).”
BackgroundInfluentialA balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
Miller, J. J., Gaiddon, C., & Storr, T. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00163e · Cited by 42
On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage
Lane, D. P., Midgley, C., Hupp, T. R., Lü, X., Vojtěšek, B., & Picksley, S. M. (1995) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1995.0013 · Cited by 51
Evaluation of ovarian findings in asymptomatic postmenopausal women with color doppler ultrasound
Vuento, M., PIRHONEN, J. P., Mäkinen, J., Laippala, P. J., Grönroos, M. A., & Salmi, T. (1995) · Cancer · doi:10.1002/1097-0142(19951001)76:7<1201::aid-cncr2820760716>3.0.co;2-l · Cited by 65
The molecular genetics of central nervous system tumors
Ng, H., & Lam, P. (1998) · Pathology · doi:10.1080/00313029800169236 · Cited by 46
Barakat, K., Issack, B. B., Stepanova, M., & Tuszynski, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027651 · Cited by 45
“Initial atomic coordinates for the DNA-bound WT p53 were obtained from the crystal structure[6] of the DBD in complex with a 21 base-pair DNA duplex (59-ATATTTGGGCAAGTCTAGGAA-39), available from the Protein Data Bank (PDB ID: 1TSR; chain B).”
BackgroundMethodDNA end recognition by the Mre11 nuclease dimer: insights into resection and repair of damaged DNA
Sung, S., Li, F., Park, Y. B., Kim, J. S., Kim, A., Song, O.-K., Kim, J., Che, J., Lee, S. E., & Cho, Y. (2014) · The EMBO Journal · doi:10.15252/embj.201488299 · Cited by 53
Self-citationImmunocytochemical analysis of the tumour suppressor protein (p53) in feline neoplasia
Nasir, L., Krasner, H., Argyle, D. J., & Williams, A. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00337-2 · Cited by 52
Paired Tumor and Normal Whole Genome Sequencing of Metastatic Olfactory Neuroblastoma
Weiss, G. J., Liang, W. S., Izatt, T., Arora, S., Cherni, I., Raju, R. N., Hostetter, G. H., Kurdoglu, A. A., Christoforides, A., Sinari, S. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037029 · Cited by 47
“The core domain structure consists of two loops (L2 and L3) and the LSH motif and this particular mutation (codon 176) is in the L2 loop [28].”
BackgroundMutDB: annotating human variation with functionally relevant data
Mooney, S. D., & Altman, R. B. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg241 · Cited by 45
“(A) The tumor suppressor gene P53 is displayed using crystal structure pdb:1TUP (Cho et al., 1994), highlighting reported cancer associated mutations.”
BackgroundWarren, R. S., Atreya, C. E., Niedzwiecki, D., WEINBERG, V. K., Donner, D. B., Mayer, R. J., Goldberg, R. M., Compton, C. C., Zuraek, M. B., Ye, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0351 · Cited by 45
“Similar to reported frequencies (9), we found that 21% (39/ 190) of the missense mutations were in L2; 22% (41/190) were in L3; and 27% (51/190) were in the LSH motif.”
BackgroundResultHegardt, C., Johannsson, O. T., & Oredsson, S. (2002) · European Journal of Biochemistry · doi:10.1046/j.0014-2956.2001.02744.x · Cited by 50
Tidow, H., Veprintsev, D. B., Freund, S. M. V., & Fersht, A. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604725200 · Cited by 45
Murakami, K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750026191 · Cited by 45
Effect of p53 Protein Redox States on Binding to Supercoiled and Linear DNA
Fojta, M., Kubičárová, T., Vojtěšek, B., & Paleček, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25749 · Cited by 45
Converting cancer genes into killer genes.
da Costa, L. T., Jen, J., He, T., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4192 · Cited by 45
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 52
Cui, F., & Zhurkin, V. B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt943 · Cited by 43
“Mutations in the p53 gene are found in 50% of human cancers and the vast majority of them occur in the sequence-specific DNA binding domain, p53DBD (9).”
Antimony Impairs Nucleotide Excision Repair: XPA and XPE as Potential Molecular Targets
Großkopf, C., Schwerdtle, T., Mullenders, L. H. F., & Hartwig, A. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100106x · Cited by 49
Horie, S., Endo, K., Kawasaki, H., & Terada, T. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000201 · Cited by 45
“MDM2, the product of the mdm2 gene, is an oncoprotein that binds to Tp53 and inhibits the p53-mediated transactivation [1, 5 , 7, 20, 21, 29, 31, 34, 37, 38, 39].”
BackgroundNew Insights into the Role of DNA Shape on Its Recognition by p53 Proteins
Golovenko, D., Bräuning, B., Vyas, P., Haran, T. E., Rozenberg, H., & Shakked, Z. (2018) · Structure · doi:10.1016/j.str.2018.06.006 · Cited by 43
The versatile interactions of p53 with DNA: when flexibility serves specificity
Kim, E. L., & Deppert, W. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401909 · Cited by 49
Update on computer-aided drug design
Jackson, R. (1995) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(95)80106-5 · Cited by 44
Monti, P., Campomenosi, P., Ciribilli, Y., Iannone, R., Aprile, A., Inga, A., Tada, M., Menichini, P., Abbondandolo, A., & Fronza, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206511 · Cited by 52
“…(one has a nonsense mutation), 56 are localized in the crystallized portion of the core of p53 (four are located outside this portion) and 35 are occurring in protein domains involved in DNA::protein interaction (L1-S2/S20-L2, H1, L3, S10-H2) (nomenclature according to Cho et al., 1994).”
BackgroundInfluentialp53: Biology and Role for Cellular Radiosensitivity
Dahm‐Daphi, J. (2000) · Strahlentherapie und Onkologie · doi:10.1007/s000660050010 · Cited by 53
“Third, the 5 particular residues are parts of the specific domains by which p53 binds to various promoters [15].”
BackgroundPeptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells
Guida, E., Bisso, A., Fenollar‐Ferrer, C., Napoli, M., Anselmi, C., Girardini, J. E., Carloni, P., & Sal, G. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0137 · Cited by 51
“The two large loops (L2 and L3) and a LSH motif (loop L1, h-strands S2 and S2’, the end of the extended h-strand S10, and the COOH-terminal helix H2) are indicated (45).”
BackgroundKanashiro, C. A., Schally, A. V., Groot, K., Armatis, P. E., Bernardino, A., & Varga, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536558100 · Cited by 44
On the origins of tumor mutations in cancer genes: insights from the p53 gene
Hollstein, M., Moeckel, G., Hergenhahn, M., Spiegelhalder, B., Keil, M., Werle‐Schneider, G., Bartsch, H., & Brickmann, J. (1998) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(98)00131-6 · Cited by 52
Senatus, P. B., Yin, L., Mandigo, C. E., NICHOLS, G. L., Moise, G., Mao, Y., Brown, M. D., Anderson, R. C. E., Parsa, A. T., Brandt‐Rauf, P. W., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0181 · Cited by 46
Furuta, S., ORTIZ, F., Sun, X. Z., Wu, H., Mason, A. Z., & Momand, J. A. (2002) · Biochemical Journal · doi:10.1042/bj20011251 · Cited by 46
The cell cycle and drug discovery: the promise and the hope
Brooks, G., & Thangue, N. B. L. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01400-2 · Cited by 45
The crisscross between p53 and metabolism in cancer
Mao, Y., & Jiang, P. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023109 · Cited by 47
“Due to the importance of zinc for the proper folding of the central core domain of p53 [101], a number of studies have shown that the addition of zinc can restore the DNA binding activity of the contact mutant p53R273H and the structural mutant p53R175H [102].”
BackgroundShen, J., van den Bogaard, E. H., Kouwenhoven, E. N., Bykov, V. J. N., Rinne, T., Zhang, Q., Tjabringa, G. S., Gilissen, C., van Heeringen, S. J., Schalkwijk, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201993110 · Cited by 43
“R273H mutant p53 retains wild-type conformation to a large extent (31).”
BackgroundCiribilli, Y., Monti, P., Bisio, A., Nguyen, H. T., Ethayathulla, A. S., Ramos, A., Foggetti, G., Menichini, P., Menendez, D., Resnick, M. A., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt657 · Cited by 43
“involved in contacting DNA (55,56), could lead to a complex change in the transactivation spectrum across many REs that also include changes in levels of transcription (39) (Supplementary Figure S1A and B).”
BackgroundLambrughi, M., GIOIA, L. D., Gervasio, F. L., Lindorff‐Larsen, K., Nussinov, R., Urani, C., Bruschi, M., & Papaleo, E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw770 · Cited by 45
“We used a subset of 40 conformations from our MD simulations of p53 DBD (95–289), both in the A-like (DNA-bound) and C-like (DNA-unbound) forms, along with the average structures from each PCA substate (Figure 1B) and available experimental structures of p53 DBD (PDB entries: 1TSR chain B (49), 2XWR chain A (50), 2GEQ…”
MethodMicroRNAs as Key Effectors in the p53 Network
Goeman, F., Strano, S., & Blandino, G. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.04.003 · Cited by 47
Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics
Kogan, S., & Carpizo, D. R. (2018) · Cancers · doi:10.3390/cancers10060166 · Cited by 47
“While DNA-contact mutations do not significantly alter p53 structure [24], they can affect protein thermostability as measured by melting temperature [25].”
BackgroundZnO nanoparticles: recent advances in ecotoxicity and risk assessment
Du, J., Tang, J., Xu, S., Ge, J., Dong, Y., Li, H., & Jin, M. (2018) · Drug and Chemical Toxicology · doi:10.1080/01480545.2018.1508218 · Cited by 50
“Cho et al. (2012) found that instilling nano-ZnO into rat lungs could cause acute and chronic inflammatory effects.”
BackgroundInfluentialArtificial Intelligence Approach to Find Lead Compounds for Treating Tumors
Chen, J., Chen, H., Dai, W.-J., Lv, Q., & Chen, C. Y. (2019) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.9b01426 · Cited by 44
Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 46
TP53 Mutants in the Tower of Babel of Cancer Progression
Bisio, A., Ciribilli, Y., Fronza, G., Inga, A., & Monti, P. (2014) · Human Mutation · doi:10.1002/humu.22514 · Cited by 49
“…primarily categorized as DNA contact mutants or structural mutants, according to the effect of the amino-acid substitution on the interaction with DNA (e.g., p.R273H) or on the structure of the TP53 protein itself (e.g., p.R175H) [Cho et al., 1994; Kitayner et al., 2006; Kitayner et al., 2010].”
BackgroundKuropkat, C., Venkatesan, T. K., Caldarelli, D. D., et al. (2002) · Auris Nasus Larynx · doi:10.1016/s0385-8146(01)00129-8 · Cited by 43
“Partial clarification may result from the recent report that p53 mutations affecting DNA contact residues are strongly prognostic in SCCHN, whereas others are not [30,32].”
BackgroundInteractions of mutant p53 with DNA: guilt by association
Kim, E. L., & Deppert, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210312 · Cited by 46
“…a co-crystal formed by the p53-DBD and a canonical p53 half-site revealed the principal features of the p53-DBD/DNA interface and formed the basis for understanding the structural premises underlying the loss of the sequence-specific transactivation function by mutp53 proteins (Cho et al., 1994).”
BackgroundSelective Pressures at a Codon-level Predict Deleterious Mutations in Human Disease Genes
Arbiza, L., Duchi, S., Montaner, D. A., Burguet, J., Pantoja‐Uceda, D., Pineda‐Lucena, A., Dopazo, J., & Dopazo, H. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.02.067 · Cited by 44
KARP-1 is induced by DNA damage in a p53- and ataxia telangiectasia mutated-dependent fashion
Myung, K., Braastad, C. D., He, D. M., & Hendrickson, E. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7664 · Cited by 43
Li, Y., Raffo, A. J., Drew, L., Mao, Y., Tran, A., Petrylak, D. P., & Fine, R. L. (2003) · PubMed · Cited by 48
Loging, W., & Reisman, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203135 · Cited by 43
“…281 p53 mutants alter residues that make contacts with the DNA target, the tertiary structure is predicted to remain for the most part unaltered (Cho et al., 1994) and to contain a functional amino terminal transcriptional regulatory domain which allow it to interact with factors such as Figure…”
BackgroundGenetic Basis of Pituitary Adenoma Invasiveness: A Review
Suhardja, A., Kovács, K., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010655419332 · Cited by 46
“The p53 protein is a 393 amino acid nuclear transcription factor [15].”
Backgroundp53 and p53 ‐regulated genes in bladder cancer
Keegan, Lunec, & Neal, D. E. (1998) · British Journal of Urology · doi:10.1046/j.1464-410x.1998.00822.x · Cited by 42
Nagata, T., & Werner, M. H. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4596 · Cited by 47
Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
Chasov, V. V., Mirgayazova, R., Zmievskaya, E., Khadiullina, R., Valiullina, A., Clarke, J. R. S., Rizvanov, A. A., Baud, M. G. J., & Bulatov, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01460 · Cited by 51
Structural basis for p53 binding to its nucleosomal target DNA sequence
Nishimura, M., Takizawa, Y., Nozawa, K., & Kurumizaka, H. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac177 · Cited by 41
“Previous crystallographic studies revealed that the p53 DBD specifically binds to the naked p53BS DNA as a tetramer (16, 17).”
BackgroundCalhoun, S., & Daggett, V. (2011) · Biochemistry · doi:10.1021/bi200192j · Cited by 42
“About 75% of mutations in sporadic and germline cancers are missense mutations (4, 5), and the majority of these occur in the DNAbinding core domain of p53 (p53C) (6).”
BackgroundJurneczko, E., Cruickshank, F. L., Porrini, M., Clarke, D. J., Campuzano, I. D. G., Morris, M. R., Nikolova, P. V., & Barran, P. E. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201210015 · Cited by 49
Genetic susceptibility to cancer: ICRP Publication 79
Approved by the Commission in May 1997 (1998) · Annals of the ICRP · doi:10.1016/s0146-6435(98)00007-3 · Cited by 68
Huidobro-Toro, J. P., Lorca, R. A., & Coddou, C. (2007) · European Biophysics Journal · doi:10.1007/s00249-007-0230-7 · Cited by 49
“Other zinc-containing enzymes are of paramount interest for tissue growth, development, and maintenance of the nervous system (Cho et al. 1994; Freemont 1993; Somers et al. 1994).”
BackgroundLepreux, S., Rebouissou, S., Bail, B. L., Saric, J., Balabaud, C. P., Bloch, B., Martin‐Négrier, M., Zucman‐Rossi, J., & Bioulac‐Sage, P. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.021 · Cited by 41
“All these mutations are located in the sequence-specific DNA binding domain (amino acid residues 100–290 out of the 393 of the p53 protein), where the majority of the mutations occurs [43,44].”
BackgroundOh, S. J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni087 · Cited by 44
“The codon 282 encodes a residue that plays a structural role in the loop–sheet–helix motif (21).”
BackgroundClark, L. S., Hart, D. W., Vojta, P. J., et al. (1998) · Mutagenesis · doi:10.1093/mutage/13.5.427 · Cited by 42
Guo, Y., Wu, H., Wiesmüller, L., & Chen, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06783-7 · Cited by 48
“The large number of oncogenic mutations found in this domain underscores its crucial role in regulating tumor suppression [13, 15, 49, 52 – 54].”
BackgroundGarufi, A., Ubertini, V., Mancini, F., D’Orazi, V., Baldari, S., Moretti, F., Bossi, G., & D’Orazi, G. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0206-x · Cited by 41
“[35] and that zinc is necessary for p53 site-specific DNA binding and proper transcriptional activation [7, 11].”
BackgroundSundar, D., Yu, Y., Katiyar, S. P., Putri, J. F., Dhanjal, J. K., Wang, J., Sari, A. N., Kolettas, E., Kaul, S. C., & Wadhwa, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1099-x · Cited by 51
Fischer, F., Grigolon, G., Benner, C., & Ristow, M. (2022) · Physiological Reviews · doi:10.1152/physrev.00017.2021 · Cited by 45
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.